{"id":1318,"date":"2020-12-22T11:30:47","date_gmt":"2020-12-22T11:30:47","guid":{"rendered":"https:\/\/touchimmunology.com\/?post_type=media_gallery&#038;p=1318"},"modified":"2021-02-23T15:11:42","modified_gmt":"2021-02-23T15:11:42","slug":"anthony-sebba-acr-2020-pain-in-patients-with-rheumatoid-arthritis-part-3","status":"publish","type":"media_gallery","link":"https:\/\/touchimmunology.com\/rheumatoid-arthritis\/conference-hub\/anthony-sebba-acr-2020-pain-in-patients-with-rheumatoid-arthritis-part-3\/","title":{"rendered":"Anthony Sebba, ACR 2020 &#8211; Pain in Patients with Rheumatoid Arthritis (Part 3)"},"content":{"rendered":"<p>After his presentation at ACR 2020, we spoke with <strong>Anthony Sebba<\/strong> (Arthritis Associates, FL, USA) about the importance of studying pain as a patient reported outcome in rheumatoid arthritis and what further studies are needed. The abstract \u2018<em>Pain and Other Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response Based on Improvement in Swollen Joints in Tocilizumab Clinical Trials.<\/em>\u2019 (ABSTRACT NUMBER: 1237) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.<\/p>\n<p><strong>Questions<\/strong><\/p>\n<ol>\n<li>What are the clinical implications of the findings from this study? (0:08)<\/li>\n<li>What further studies are needed? (7:11)<\/li>\n<\/ol>\n<p><strong>Disclosures:<\/strong> Consultant or speaker for Genentech, Sanofi, Lilly, Gilead and Amgen.<\/p>\n<p><strong>Support:<\/strong> Interview and filming supported by Touch Medical Media.<\/p>\n<p><strong>Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>After his presentation at ACR 2020, we spoke with Anthony Sebba (Arthritis Associates, FL, USA) about the importance of studying pain as a patient reported outcome in rheumatoid arthritis and what further studies are needed. The abstract \u2018Pain and Other Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response [&hellip;]<\/p>\n","protected":false},"featured_media":1314,"template":"","class_list":["post-1318","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-rheumatoid-arthritis","video_categories-acr-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/1318","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":3,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/1318\/revisions"}],"predecessor-version":[{"id":1329,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/1318\/revisions\/1329"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media\/1314"}],"wp:attachment":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media?parent=1318"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}